Title:Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis
Volume: 22
Issue: 4
Author(s): Selvakumar Muruganantham, Venkateshwaran Krishnaswami, Shanmugarathinam Alagarsamy and Ruckmani Kandasamy*
Affiliation:
- Centre for Excellence in Nanobio Translational Research (CENTRE), Department of Pharmaceutical Technology, University College of Engineering, Anna University, BIT Campus, Tiruchirappalli, Tamil Nadu,India
Keywords:
Atherothrombosis, platelets, anti-thrombotic drugs, formulations, cardiovascular ischemic events, pharmaceutical.
Abstract: Atherothrombosis results from direct interaction between atherosclerotic plaque and arterial
thrombosis and is the most common type of cardiovascular disease. As a long term progressive
disease, atherosclerosis frequently results in an acute atherothrombotic event through plaque rupture
and platelet-rich thrombus formation. The pathophysiology of atherothrombosis involves
cholesterol accumulation endothelial dysfunction, dyslipidemia, immuno-inflammatory, and apoptotic
aspects. Platelet activation and aggregation is the major cause for stroke because of its roles,
including thrombus, contributing to atherosclerotic plaque, and sealing off the bleeding vessel.
Platelet aggregates are associated with arterial blood pressure and cardiovascular ischemic events.
Under normal physiological conditions, when a blood vessel is damaged, the task of platelets
within the circulation is to arrest the blood loss. Antiplatelet inhibits platelet function, thereby decreasing
thrombus formation with complementary modes of action to prevent atherothrombosis. In
the present scientific scenario, researchers throughout the world are focusing on the development
of novel drug delivery systems to enhance patient’s compliance. Immediate responding pharmaceutical
formulations become an emerging trend in the pharmaceutical industries with better patient
compliance. The proposed review provides details related to the molecular pathogenesis of
atherothrombosis and recent novel formulation approaches to treat atherothrombosis with particular
emphasis on commercial formulation and upcoming technologies.
